From mice to men: Insights into the insulin resistance syndromes

Annual Review of Physiology

Volumn 68, Issue , 2006, Pages 123-158

  Biddinger, Sudha B ^a,b   Kahn, C Ronald ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR;

CANCER; CARDIOVASCULAR DISEASE; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; INSULIN; INSULIN RESISTANCE; MICE; MICE, KNOCKOUT; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 33645982255     PISSN: 00664278     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.physiol.68.040104.124723     Document Type: Review

References (161)

1. Ford ES, Giles WH, Mokdad AH. 2004. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 27:2444-49
2. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, et al. 2004. Obesity and the metabolic syndrome in children and adolescents. N. Engl. J. Med. 350:2362-74
3. Reaven G. 2004. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol. Metab. Clin. North Am. 33:283-303
4. 3a. Chang PY, Benecke H, Le Marchand-Brustel Y, Lawitts J, Moller DE. 1994. Expression of a dominant-negative mutant human insulin receptor in the muscle of transgenic mice. J. Biol. Chem. 269:16034-40
5. 3b. Fernandez AM, Kim JK, Yakar S, Dupont J, Hernandez-Sanchez C, et al. 2001. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Gene Dev. 15:1926-34
6. Bruning JC, Michael MD, Winnay JN, Hayashi T, Horsch D, et al. 1998. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol. Cell 2:559-69
7. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, et al. 2000. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell 6:87-97
8. Fisher SJ, Kahn CR. 2003. Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production. J. Clin. Invest. 111:463-68
9. 6a. Hernandez-Ono A, Zhang Y-L, Chiang J, Moon B, Kahn CR, et al. 2005. Lipoprotein metabolism in the liver insulin receptor knockout (LIRKO) mouse: critical role of insulin signaling in the regulation of very low density lipoprotein (VLDL) secretion. Diabetes 54(Suppl. 1):A2(Abstr.)
10. Zierath JR, Wallberg-Henriksson H. 2002. From receptor to effector: insulin signal transduction in skeletal muscle from type II diabetic patients. Ann. NY Acad. Sci. 967:120-34
11. Martin BC, Wjkabrsjk CR. 1992. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340:925-29
12. Kim JK, Michael MD, Previs SF, Peroni OD, Mauvais-Jarvis F, et al. 2000. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J. Clin. Invest. 105:1791-97
13. Cariou B, Postic C, Boudou P, Burcelin R, Kahn CR, et al. 2004. Cellular and molecular mechanisms of adipose tissue plasticity in muscle insulin receptor knockout mice. Endocrinology 145:1926-32
14. Bluher M, Michael MD, Peroni OD, Ueki K, Carter N, et al. 2002. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev. Cell 3:25-38
15. Bluher M, Patti M, Kahn C. 2004. Intrinsic heterogeneity in adipose tissue-insulin receptor knockout is associated with differences in metabolic function and in gene expression patterns revealed by microarray analysis. J. Biol. Chem. 279:31891-901
16. Bluher M, Wilson-Fritch L, Leszyk J, Laustsen P, Corvera S, Kahn C. 2004. Role of insulin action and cell size on protein expression patterns in adipocytes. J. Biol. Chem. 279:31902-9
17. Bluher M, Kahn BB, Kahn CR. 2003. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299:572-74
18. Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R. 1993. A C. elegans mutant that lives twice as long as wild type. Nature 366:461-64
19. Kimura KD, Tissenbaum HA, Liu Y, Ruvkun G. 1997. daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science 277:942-46
20. Wolkow CA, Kimura KD, Lee MS, Ruvkun G. 2000. Regulation of C. elegans life-span by insulinlike signaling in the nervous system. Science 290:147-50
21. Tatar M, Kopelman A, Epstein D, Tu MP, Yin CM, Garofalo RS. 2001. A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. Science 292:107-10
22. Clancy DJ, Gems D, Harshman LG, Oldham S, Stocker H, et al. 2001. Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein. Science 292:104-6
23. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. 1999. Tissue-specific knockout of the insulin receptor in pancreatic β cells creates an insulin secretory defect similar to that in Type 2 diabetes. Cell 96:329-39
24. Gunton JE, Kulkarni RN, Yim S, Okada T, Hawthorne WJ, et al. 2005. Loss of ARNT/HIF1β mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell 122:337-49
25. Etgen GJ Jr, Fryburg DA, Gibbs EM. 1997. Nitric oxide stimulates skeletal muscle glucose transport through a calcium/contraction- and phosphatidylinositol-3-kinase-independent pathway. Diabetes 46:1915-19
26. Young ME, Radd GK, Leighton B. 1997. Nitric oxide stimulates glucose transport and metabolism in rat skeletal muscle in vitro. Biochem. J. 322:223-28
27. Vicent D, Ilany J, Kondo T, Naruse K, Fisher SJ, et al. 2003. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J. Clin. Invest. 111:1373-80
28. Kondo T, Vicent D, Suzuma K, Yanagisawa M, King GL, et al. 2003. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J. Clin. Invest. 111:1835-42
29. Havrankova J, Brownstein M, Roth J. 1981. Insulin and insulin receptors in rodent brain. Diabetologia 20:268-73
30. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, et al. 2000. Role of brain insulin receptor in control of body weight and reproduction. Science 289:2122-25
31. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, et al. 2004. Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. USA 101:3100-5
32. Obici S, Feng Z, Karkanias G, Baskin DG, Rossetti L. 2002. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat. Neurosci. 5:566-72
33. ATP channels control hepatic glucose production. Nature 434:1026-31
34. Mauvais-Jarvis F, Virkamaki A, Michael MD, Winnay JN, Zisman A, et al. 2000. A model to explore the interaction between muscle insulin resistance and β-cell dysfunction in the development of type 2 diabetes. Diabetes 49:2126-34
35. Accili D, Drago J, Lee EJ, Johnson MD, Cool MH, et al. 1996. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat. Genet. 12:106-9
36. Okamoto H, Nakae J, Kitamura T, Park BC, Dragatsis I, Accili D. 2004. Transgenic rescue of insulin receptor-deficient mice. J. Clin. Invest. 114:214-23
37. Buettner C, Patel R, Muse ED, Bhanot S, Monia BP, et al. 2005. Severe impairment in liver insulin signaling fails to alter hepatic insulin action in conscious mice. J. Clin. Invest. 115:1306-13
38. Taylor SI, Arioglu E. 1998. Syndromes associated with insulin resistance and acanthosis nigricans. J. Basic Clin. Physiol. Pharmacol. 9:419-39
39. Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, et al. 1976. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N. Engl. J. Med. 294:739-45
40. Baron V, Kaliman P, Gautier N, Van Obberghen E. 1992. The insulin receptor activation process involves localized conformational changes. J. Biol. Chem. 267:23290-94
41. Ablooglu AJ, Kohanski RA. 2001. Activation of the insulin receptor's kinase domain changes the rate-determining step of substrate phosphorylation. Biochemistry 40:504-13
42. Sun XJ, Rothenberg PL, Kahn CR, Backer JM, Araki E, et al. 1991. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352:73-77
43. Sun XJ, Wang LM, Zhang Y, Yenush L, Myers MG Jr, et al. 1995. Role of IRS-2 in insulin and cytokine signalling. Nature 377:173-77
44. Lavan BE, Lane WS, Lienhard GE. 1997. The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. J. Biol. Chem. 272:11439-43
45. Lavan BE, Fantin VR, Chang ET, Lane WS, Keller SR, Lienhard GE. 1997. A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic kidney cells is a new member of the insulin receptor substrate family. J. Biol. Chem. 272:21403-7
46. White MF, Yenush L. 1998. The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Curr. Top. Microbiol. Immunol. 228:179-208
47. Fantin VR, Lavan BE, Wang Q, Jenkins NA, Gilbert DJ, et al. 1999. Cloning, tissue expression, and chromosomal location of the mouse insulin receptor substrate 4 gene. Endocrinology 140:1329-37
48. Sciacchitano S, Taylor SI. 1997. Cloning, tissue expression, and chromosomal localization of the mouse IRS-3 gene. Endocrinology 138:4931-40
49. Inoue G, Cheatham B, Emkey R, Kahn CR. 1998. Dynamics of insulin signaling in 3T3-L1 adipocytes. Differential compartmentalization and trafficking of insulin receptor substrate (IRS)-1 and IRS-2. J. Biol. Chem. 273:11548-55
50. Kaburagi Y, Satoh S, Yamamoto-Honda R, Ito T, Ueki K, et al. 2001. Insulin-independent and wortmannin-resistant targeting of IRS-3 to the plasma membrane via its pleckstrin homology domain mediates a different interaction with the insulin receptor from that of IRS-1. Diabetologia 44:992-1004
51. Lassak A, Del Valle L, Peruzzi F, Wang IY, Enam S, et al. 2002. Insulin receptor substrate 1 translocation to the nucleus by the human IC virus T-antigen. J. Biol. Chem. 277:17231-38
52. Kabuta T, Hakuno F, Asano T, Takahashi S. 2002. Insulin receptor substrate-3 functions as transcriptional activator in the nucleus. J. Biol. Chem. 277:6846-51
53. Gustafson TA, He W, Craparo A, Schaub CD, O'Neill TI. 1995. Phosphotyrosine-dependent interaction of She and IRS-1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain. Mol. Cell Biol. 15:2500-8
54. Boney CM, Gruppuso PA, Faris RA, Frackelton AR Jr. 2000. The critical role of She in insulin-like growth factor-I-mediated mitogenesis and differentiation in 3T3-L1 preadipocytes. Mol. Endocrinol. 14:805-13
55. Baumann CA, Ribon V, Kanzaki M, Thurmond DC, Mora S, et al. 2000. CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature 407:202-7
56. Wick MJ, Dong LQ, Hu D, Langlais P, Liu F. 2001. Insulin receptor-mediated p62dok tyrosine phosphorylation at residues 362 and 398 plays distinct roles for binding GTPase-activating protein and Nck and is essential for inhibiting insulin-stimulated activation of Ras and Akt. J. Biol. Chem. 276:42843-50
57. Lehr S, Kotzka J, Herkner A, Sikmann A, Meyer HE, et al. 2000. Identification of major tyrosine phosphorylation sites in the human insulin receptor substrate Gab-1 by insulin receptor kinase in vitro. Biochemistry 39:10898-907
58. Shepherd PR, Withers DJ, Siddle K. 1998. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem. J. 333:471-90
59. Vanhaesebroeck B, Alessi DR. 2000. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 346(Pt. 3):561-76
60. Inukai K, Funaki M, Ogihara T, Katagiri H, Kanda A, et al. 1997. p85α gene generates three isoforms of regulatory subunit for phosphatidylinositol 3-kinase (PI 3-kinase), p50α, p55α, and p85α, with different PI 3-kinase activity elevating responses to insulin. J. Biol. Chem. 272:7873-82
61. Antonetti DA, Algenstaedt P, Kahn CR. 1996. Insulin receptor substrate 1 binds two novel splice variants of the regulatory subunit of phosphatidylinositol 3-kinase in muscle and brain. Mol. Cell. Biol. 16:2195-203
62. Carpenter CL, Cantley LC. 1996. Phosphoinositide kinases. Curr. Opin. Cell Biol. 8:153-58
63. Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J, Kahn CR. 1994. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol. Cell. Biol. 14:4902-11
64. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, et al. 2001. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell. Biol. 3:1009-13
65. Nakae J, Kitamura T, Silver DL, Accili D. 2001. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J. Clin. Invest. 108:1359-67
66. Kohn AD, Summers SA, Birnbaum MJ, Roth RA. 1996. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J. Biol. Chem. 271:31372-78
67. Bandyopadhyay G, Standaert ML, Zhao L, Yu B, Avignon A, et al. 1997. Activation of protein kinase C (α, β, and ζ) by insulin in 3T3/L1 cells. Transfection studies suggest a role for PKC-ζ in glucose transport. J. Biol. Chem. 272:2551-58
68. Bandyopadhyay G, Standaert ML, Kikkawa U, Ono Y, Moscat J, Farese RV. 1999. Effects of transiently expressed atypical (ζ, λ), conventional (α, β) and novel (δ, ε) protein kinase C isoforms on insulin-stimulated translocation of epitope-tagged GLUT4 glucose transporters in rat adipocytes: specific interchangeable effects of protein kinases C-ζ and C-λ. Biochem J. 337(Pt. 3):461-70
69. Kotani K, Ogawa W, Matsumoto M, Kitamura T, Sakaue H, et al. 1998. Requirement of atypical protein kinase λ for insulin stimulation of glucose uptake but not for akt activation in 3T3-L1 adipocytes. Mol. Cell. Biol. 18:6971-82
70. Sajan MP, Standaert ML, Miura A, Kahn CR, Farese RV. 2004. Tissue-specific differences in activation of atypical protein kinase C and protein kinase B in muscle, liver, and adipocytes of insulin receptor substrate-1 knockout mice. Mol. Endocrinol. 18:2513-21
71. Gille H, Kortenjann M, Thomae O, Moomaw C, Slaughter C, et al. 1995. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J. 14:951-62
72. ras activation in the metabolic signaling by insulin. J. Biol. Chem. 270:2036-40
73. Horton JD, Goldstein JL, Brown MS. 2002. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109:1125-31
74. Yamamoto T, Shimano H, Nakagawa Y, Ide T, Yahagi N, et al. 2004. SREBP-1 interacts with hepatocyte nuclear factor-4 α and interferes with PGC-1 recruitment to suppress hepatic gluconeogenic genes. J. Biol. Chem. 279:12027-35
75. Tontonoz P, Kim JB, Graves RA, Spiegelman BM. 1993. ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol. Cell. Biol. 13:4753-59
76. Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS, Goldstein JL. 1999. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc. Natl. Acad. Sci. USA 96:13656-61
77. Horton JD, Bashmakov Y, Shimomura I, Shimano H. 1998. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc. Natl. Acad. Sci. USA 95:5987-92
78. Azzout-Marniche D, Becard D, Guichard C, Foretz M, Ferre P, Foufelle F. 2000. Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes. Biochem. J. 350(Pt. 2):389-93
79. Matsumoto M, Ogawa W, Teshigawara K, Inoue H, Miyake K, et al. 2002. Role of the insulin receptor substrate 1 and phosphatidylinositol 3-kinase signaling pathway in insulin-induced expression of sterol regulatory element binding protein 1c and glucokinase genes in rat hepatocytes. Diabetes 51:1672-80
80. Matsumoto M, Ogawa W, Akimoto K, Inoue H, Miyake K, et al. 2003. PKCλ in liver mediates insulin-induced SREBP-1c expression and determines both hepatic lipid content and overall insulin sensitivity. J. Clin. Invest. 112:935-44
81. Fleischmann M, Iynedjian PB. 2000. Regulation of sterol regulatory-element binding protein 1 gene expression in liver: role of insulin and protein kinase B/cAkt. Biochem. J. 349:13-17
82. Chen G, Liang G, Ou J, Goldstein JL, Brown MS. 2004. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc. Natl. Acad. Sci. USA 101:11245-50
83. Yabe D, Komuro R, Liang G, Goldstein JL, Brown MS. 2003. Liver-specific mRNA for Insig-2 down-regulated by insulin: implications for fatty acid synthesis. Proc. Natl. Acad. Sci. USA 100:3155-60
84. Kotzka J, Muller-Wieland D, Koponen A, Njamen D, Kremer L, et al. 1998. ADD1/SREBP-1c mediates insulin-induced gene expression linked to the MAP kinase pathway. Biochem. Biophys. Res. Commun. 249:375-79
85. Kim KH, Song MJ, Yoo EJ, Choe SS, Park SD, Kim JB. 2004. Regulatory role of glycogen synthase kinase 3 for transcriptional activity of ADD1/SREBP1c. J. Biol. Chem. 279:51999-2006
86. Inoki K, Li Y, Xu T, Guan KL. 2003. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17:1829-34
87. Inoki K, Li Y, Zhu T, Wu J, Guan KL. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell. Biol. 4:648-57
88. Gao X, Zhang Y, Arrazola P, Hino O, Kobayashi T, et al. 2002. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell. Biol. 4:699-704
89. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-101
90. Abe H, Yamada N, Kamata K, Kuwaki T, Shimada M, et al. 1998. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J. Clin. Invest. 101:1784-88
91. Araki E, Lipes MA, Patti ME, Bruning JC, Haag B III, et al. 1994. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372:186-90
92. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, et al. 1998. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391:900-4
93. Kubota N, Tobe K, Terauchi Y, Eto K, Yamauchi T, et al. 2000. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory β-cell hyperplasia. Diabetes 49:1880-89
94. Kubota T, Kubota N, Moroi M, Terauchi Y, Kobayashi T, et al. 2003. Lack of insulin receptor substrate-2 causes progressive neointima formation in response to vessel injury. Circulation 107:3073-80
95. Taniguchi CM, Ueki K, Kahn R. 2005. Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J. Clin. Invest. 115:718-27
96. Liu SC, Wang Q, Lienhard GE, Keller SR. 1999. Insulin receptor substrate 3 is not essential for growth or glucose homeostasis. J. Biol. Chem. 274:18093-99
97. Fantin VR, Wang GE, Lienhard GE, Keller SR. 2000. Mice lacking insulin receptor substrate 4 exhibit mild defects in growth, reproduction, and glucose homostasis. Am. J. Physiol. 278:E127-33
98. Bard-Chapeau EA, Hevener AL, Long S, Zhang EE, Olefsky JM, Feng GS. 2005. Deletion of Gab1 in the liver leads to enhanced glucose tolerance and improved hepatic insulin action. Nat. Med. 11:567-71
99. Tsuruzoe K, Emkey R, Kriauciunas KM, Ueki K, Kahn CR. 2001. Insulin receptor substrate 3 (IRS-3) and IRS-4 impair IRS-1- and IRS-2-mediated signaling. Mol. Cell. Biol. 21:26-38
100. Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, White MF. 1999. Irs-2 coordinates Igf-1 receptor-mediated β-cell development and peripheral insulin signalling. Nat. Genet. 23:32-40
101. -/- double knockout mice. Genes Dev. 16:3213-22
102. Terauchi Y, Matsui J, Suzuki R, Kubota N, Komeda K, et al. 2003. Impact of genetic background and ablation of insulin receptor substrate (IRS)-3 on IRS-2 knock-out mice. J. Biol. Chem. 278:14284-90
103. Fruman DA, Mauvais-Jarvis F, Pollard DA, Yballe CM, Brazil D, et al. 2000. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85a. Nat. Genet. 26:379-82
104. Terauchi Y, Tsuji T, Satoh S, Minoura H, Murakami K, et al. 1999. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3-kinase. Nat. Genet. 21:230-35
105. Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K, et al. 2002. Reduced expression of the murine p85α subunit of phosphoinositide 3-kinase improves insulin signaling and amelio-rates diabetes. J. Clin. Invest. 109:141-49
106. 102a. Ueki K, Yballe CM, Brachmann SM, Vicent D, Watt JM, et al. 2002. Increased insulin sensitivity in mice lacking p85β subunit of phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. USA 99:419-24
107. Chen D, Mauvais-Jarvis F, Bluher M, Fisher SJ, Jozsi A, et al. 2004. p50α/p55α phosphoinositide 3-kinase knockout mice exhibit enhanced insulin sensitivity. Mol. Cell. Biol. 24:320-29
108. Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR. 2002. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol. Cell. Biol. 22:965-77
109. Harbour LA, Shao J, Qiao L, Leitner W, Anderson M, et al. 2004. Human placental growth hormone increases expression of the p85 regulatory unit of phosphatidylinositol 3-kinase and triggers severe insulin resistance in skeletal muscle. Endocrinology 145:1144-50
110. Brachmann SM, Ueki K, Engelman JA, Kahn RC, Cantley LC. 2005. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol. Cell. Biol. 25:1596-607
111. Bi L, Okabe I, Bernard DJ, Nussbaum RL. 2002. Early embryonic lethality in mice deficient in the p110β catalytic subunit of PI 3-kinase. Mamm. Genome 13:169-72
112. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. 1999. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase. J. Biol. Chem. 274:10963-68
113. MacDonald PE, Joseph JW, Yau D, Diao J, Asghar Z, et al. 2004. Impaired glucose-stimulated insulin secretion, enhanced intraperitoneal insulin tolerance, and increased β-cell mass in mice lacking the p110γ isoform of phosphoinositide 3-kinase. Endocrinology 145:4078-83
114. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. 2001. Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276:38349-52
115. Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, et al. 2005. Role for Akt3/protein kinase Bγ in attainment of normal brain size. Mol. Cell. Biol. 25:1869-78
116. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, et al. 2001. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 292:1728-31
117. Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, et al. 2003. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB β. J. Clin. Invest. 112:197-208
118. Woulfe D, Jiang H, Morgans A, Monks R, Birnbaum M, Brass LF. 2004. Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. J. Clin. Invest. 113:441-50
119. Bernal-Mizrachi E, Fatrai S, Johnson JD, Ohsugi M, Otani K, et al. 2004. Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet β cells. J. Clin. Invest. 114:928-36
120. Ono H, Shimano H, Katagiri H, Yahagi N, Sakoda H, et al. 2003. Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement. Diabetes 52:2905-13
121. Bost F, Aouadi M, Caron L, Even P, Belmonte N, et al. 2005. The extracellular signal-regulated kinase isoform ERK1 is specifically required for in vitro and in vivo adipogenesis. Diabetes 54:402-11
122. Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS. 2002. Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J. Biol. Chem. 277:9520-28
123. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, et al. 2001. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844-50
124. Yu AS, Keeffe EB. 2002. Nonalcoholic fatty liver disease. Rev. Gastroenterol. Disord. 2:11-19
125. Biddinger SB, Almind K, Miyazaki M, Kokkotou E, Ntambi JM, Kahn CR. 2005. Effects of diet and genetic background on sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome. Diabetes 54:1314-23
126. Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, et al. 1998. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev. 12:3182-94
127. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. 1999. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73-76
128. Rui L, Fisher TL, Thomas J, White MF. 2001. Regulation of insulin/insulin-like growth factor-1 signaling by proteasome-mediated degradation of insulin receptor substrate-2. J. Biol. Chem. 276:40362-67
129. Zhande R, Mitchell JJ, Wu J, Sun XJ. 2002. Molecular mechanism of insulin-induced degradation of insulin receptor substrate 1. Mol. Cell. Biol. 22:1016-26
130. Bar RS, Harrison LC, Muggeo M, Gorden P, Kahn CR, Roth J. 1979. Regulation of insulin receptors in normal and abnormal physiology in humans. Adv. Int. Med. 24:23-52
131. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. 2000. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell 6:77-86
132. Ide T, Shimano H, Yahagi N, Matsuzaka T, Nakakuki M, et al. 2004. SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat. Cell Biol. 6:351-57
133. Liu YF, Paz K, Herschkovitz A, Alt A, Tennenbaum T, et al. 2001. Insulin stimulates PKCλ-mediated phosphorylation of insulin receptor substrate-1 (IRS-1). J. Biol. Chem. 276:14459-65
134. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, et al. 2002. A central role for JNK in obesity and insulin resistance. Nature 420:333-36
135. Gao Z, Hwang D, Bataille F, Lefevre M, York D, et al. 2002. Serine phosphorylation of insulin receptor substrate 1 (IRS-1) by inhibitor kappa B kinase (IKK) complex. J. Biol. Chem. 277:48115-21
136. Craparo A, Freund R, Gustafson TA. 1997.14-3-3 ε interacts with the insulin-like growth factor I receptor and insulin receptor substrate I in phosphotyrosine-independent manner. J. Biol. Chem. 272:11663-70
137. Emanuelli B, Peraldi P, Filloux C, Sawka-Verheile D, Hilton D, Van Obberghen E. 2000. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J. Biol. Chem. 275:15985-91
138. Rui L, Yuan M, Frantz D, Shoelson S, White MF. 2002. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 277:42394-98
139. Nakashima N, Sharma PM, Imamura T, Bookstein R, Olefsky J. 2000. The tumor suppressor PTEN negatively regulates insulin signaling in 3T3-L1 adipocytes. J. Biol. Chem. 275:12889-95
140. Clement S, Krause U, Desmedt F, Tanti JF, Behrends J, et al. 2001. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 409:92-97
141. Cohen P, Miyazaki M, Socci ND, Hagge-Greenberg A, Liedtke W, et al. 2002. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 297:240-43
142. Saad MJA, Araki E, Miralpeix M, Rothenberg PL, White MF, Kahn CR. 1992. Regulation of insulin receptor substrate 1 in liver and muscle of animal models of insulin resistance. J. Clin. Invest. 90:1839-49
143. Kerouz NJ, Horsch D, Pons S, Kahn CR. 1997. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J. Clin. Invest. 100:3164-72
144. Kondo T, Kahn CR. 2004. Altered insulin signaling in retinal tissue in diabetic states. J. Biol. Chem. 279:37997-8006
145. Standaert ML, Sajan MP, Miura A, Kanoh Y, Chen HC, et al. 2004. Insulin-induced activation of atypical protein kinase C, but not protein kinase B, is maintained in diabetic (ob/ob and Goto-Kakazaki) liver. Contrasting insulin signaling patterns in liver versus muscle define phenotypes of type 2 diabetic and high fat-induced insulin-resistant states. J. Biol. Chem. 279:24929-34
146. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, et al. 2002. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J. Biol. Chem. 277:19353-57
147. Bray GA. 1984. Hypothalamic and genetic obesity: an appraisal of the autonomic hypothesis and the endocrine hypothesis. Int. J. Obes. 8(Suppl. 1):119-37
148. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, et al. 1999. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J. Clin. Invest. 104:447-57
149. Anai M, Funaki M, Ogihara T, Kanda A, Onishi Y, et al. 1999. Enhanced insulin-stimulated activation of phosphatidylinositol 3-kinase in the liver of high-fat-fed rats. Diabetes 48:158-69
150. Saad MJA, Folli F, Kahn JA, Kahn CR. 1993. Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J. Clin. Invest. 92:2065-72
151. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, et al. 2000. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J. Clin. Invest. 105:311-20
152. Goodyear LJ, Giorgino F, Sherman LA, Carey J, Smith RJ, Dohm GL. 1995. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J. Clin. Invest. 95:2195-204
153. Kim YB, Nikoulina SE, Ciaraldi TP, Henry RR, Kahn BB. 1999. Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J. Clin. Invest. 104:733-41
154. Deleted in proof
155. Sinha MK, Taylor LG, Pories WJ, Flickinger EG, Meelheim D, et al. 1987. Long-term effect of insulin on glucose transport and insulin binding in cultured adipocytes from normal and obese humans with and without non-insulin-dependent diabetes. J. Clin. Invest. 80:1073-81
156. Caro JF, Dohm LG, Pories WJ, Sinha MK. 1989. Cellular alterations in liver, skeletal muscle, and adipose tissue responsible for insulin resistance in obesity and type II diabetes. Diabetes Metab. Rev. 5(8):665-89
157. Freidenberg GR, Henry RR, Klein HH, Reichart DR, Olefsky JM. 1987. Decreased kinase activity of insulin receptors from adipocytes of non-insulin dependent diabetic subjects. J. Clin. Invest. 79:240-50
158. Takayama S, Kahn CR, Kubo K, Foley JE. 1988. Alterations in insulin receptor autophosphorylation in insulin resistance: correlation with altered sensitivity to glucose transport and antilipolysis to insulin. J. Clin. Endocrinol. Metab. 6:992-99
159. Foley JE. 1988. Mechanisms of impaired insulin action in isolated adipocytes from obese and diabetic subjects. Diabetes Metab. Rev. 4:487-505
160. Lockwood DH, Amatruda JM. 1983. Cellular alterations responsible for insulin resistance in obesity and type II diabetes mellitus. Am. J. Med. 75:23-31
161. Caro JF, Ittoop O, Pories WJ, Meelheim D, Flickinger EG, et al. 1986. Studies on the mechanism of insulin resistance in the liver from humans with noninsulin-dependent diabetes. J. Clin. Invest. 78:249-58